UNSPSC 51386205: Olsalazine sodium

This classification denotes an anti-infective agent, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier Y7JEW0XG7I. European Medicines Agency schedules Olsalazine sodium in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB03510MIG. Olsalazine sodium generally arises in the molecular formula C14H8N2O6.2NA. The term 'olsalazine sodium' is a United States Adopted Name designation. Most nations, for tariff and trade purposes, schedule olsalazine sodium under HS 32041200 and SITC 53112.

As of Q4 2014, OLSALAZINE SODIUM remains US FDA's Preferred Term for this commodity. Olsalazine sodium bears US NLM identifiers UMLS ID C0353940 and NCI Concept Code C66254. SMILES: C1CC(C(CC1/N=N/C2CCC(C(C2)C(=O)[O-])O)C(=O)[O-])O.[NA+].[NA+].

UNSPSC 51386205 Olsalazine sodium is a Commodity code that in recent state and local procurement does not map to the pharmaceutical active ingredient its name suggests. The three most recent opportunities tagged to this code involve naloxone and drug deactivation systems, direct-to-manufacturer pharmacy programs, and generic multi-source pharmaceuticals and OTC products — none of which target olsalazine sodium specifically. The code sees activity from state health and human services agencies, county health departments, and multistate cooperative purchasing alliances procuring pharmaceutical products and systems at scale for public health and employee benefit programs. Issuing bodies include county governments (Seminole County, Florida), state health commissions (Texas Health and Human Services Commission), and cooperative purchasing vehicles (Minnesota Multistate Cooperative Purchasing Alliance, or MMCAP).

Recent opportunities span Florida, Texas, Minnesota, and Oregon. Seminole County issued IFB 60459723LAS on June 30, 2026, seeking 1,900 units of naloxone and 800 safe drug deactivation systems annually through July 26, 2023 (note: the due date appears to predate the posting date in the source), with quarterly deliveries to the Seminole County Community Health Building in Sanford, Florida and a two-year initial term plus one-year renewal option. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, requesting vendor capabilities for a direct-to-manufacturer prescription program outside traditional pharmacy benefit manager and group purchasing organization channels, with responses due the same day. MMCAP, administered by the Minnesota Department of Administration's Office of State Procurement and serving participating jurisdictions including Oregon, issued RFP S1070000015802 on January 20, 2026, for generic multi-source pharmaceuticals and OTC products through three authorized wholesalers, with proposals due March 26, 2026, and awards effective July 1, 2026. The code shows misalignment between its nominal scope and actual recent procurements; olsalazine sodium does not appear in any of the three opportunities.